TORONTO, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) will be holding its Annual General Meeting at 10:00 am, local time, on August 28, 2015, at the principal offices of the Company located at 421 Comstock Road, Toronto, Ontario, Canada, M1L 2H5.
The Company has previously announced the inaugural use of online voting and encourages registered shareholders to ensure their votes are counted by carefully following the instructions on the Notice Card, mailed on July 17, 2015, to shareholders of record as of June 17, 2015. The Notice Card provides important instructions on how to cast your vote electronically.
Shareholders are reminded to vote. Should you have any problems or concerns please contact Linda Hughes at 1-877-945-1621, or Sharon Wardlaw at 416-755-2231. You may fax your votes to 416-755-0334.
The Company’s Annual Report and Proxy Statement for the year ended January 31, 2015 are available on the Company website www.Polydex.com. The Proxy Statement contains additional information regarding the proposals to be considered and voted upon at the Annual General Meeting and shareholders are encouraged to read it in its entirety.
The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet platform (www.otcmarkets.com/stock/POLXF/quote).
The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com. Product information is available at www.dextran.ca
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company’s filings with the United States Securities and Exchange Commission may also affect the actual results achieved by the Company.
CONTACT: Investor Relations: North Arm Capital Services, Linda Hughes, 1-877-945-1621, (Linda@northarm.com)
Help employers find you! Check out all the jobs and post your resume.